A randomised, placebo-controlled trial of Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia in chronic kidney disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1008604

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatments.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $345,189.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anaemia | erythropoietin | inflammation | nephrology | oxidative stress | pharmacokinetics

Related Links